Dr. Olsson on Differences Between LHRH Agonists and Antagonists in Prostate Cancer

Carl Olsson, MD
Published Online: Thursday, Jan 19, 2017



Carl Olsson, MD, Integrated Medical Professionals, compares the efficacy of LHRH agonists with antagonists, which are commonly used to treat patients with prostate cancer.

The use of the LHRH analog has been around for a long time, Olsson explains. To think about the best way to develop an agent, it would be to develop an antagonist versus an agonist, he adds. This is because the majority of drugs are agonists. Though they are effective and lower testosterone, they also accelerate the testosterone first. The best way to do this would be through drug management in order to develop an antagonist at the outset. That was very different biochemically, which is why researchers dealt with agonists primarily.

There was 1 antagonist that did have efficacy, but the side effect profile was too high. There is a second antagonist, he adds, which is showing promise in the prostate cancer field.


Carl Olsson, MD, Integrated Medical Professionals, compares the efficacy of LHRH agonists with antagonists, which are commonly used to treat patients with prostate cancer.

The use of the LHRH analog has been around for a long time, Olsson explains. To think about the best way to develop an agent, it would be to develop an antagonist versus an agonist, he adds. This is because the majority of drugs are agonists. Though they are effective and lower testosterone, they also accelerate the testosterone first. The best way to do this would be through drug management in order to develop an antagonist at the outset. That was very different biochemically, which is why researchers dealt with agonists primarily.

There was 1 antagonist that did have efficacy, but the side effect profile was too high. There is a second antagonist, he adds, which is showing promise in the prostate cancer field.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication